metolazone (zaroxolyn) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Metolazone is a thiazide-like diuretic marketed under the brand names Mykrox and Zaroxolyn. Zaroxolyn is indicated for the treatment of salt and water retention including: • Edema accompanying congestive heart failure; • Edema accompanying renal diseases including the nephrotic syndrome and states of diminished renal function. Zaroxolyn is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of Metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. A proximal action of Metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.   NCATS

Chemistry

  • SMILES: CC1NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)C(=O)N1C3=CC=CC=C3C
  • InChIKey: AQCHWTWZEMGIFD-UHFFFAOYSA-N
  • Mol. Mass: 365.835
  • ALogP: 2.71
  • ChEMBL Molecule:
    metolazone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3195 - $2.0132
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone | 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide | 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide | diulo | metenix | metolazon | metolazona | metolazone | métolazone | metolazonum | metozalone | mykrox | sr72022 | sr-720-22 | xuret | zaroloxyn | zaroxolyn

Organizations (45)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (2)


 

Heart Failure

Hypertension (approved 1973)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Body Fluids (Phase 4)

Cardiomyopathies (Phase 1)

Cardiovascular Diseases (Phase 4)

Healthy Volunteers (Phase 1)

Heart Failure ()

Heart Failure, Systolic (Phase 4)

Kidney Failure, Chronic (Phase 2)

Pharmacology (Phase 4)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue